CHDI FOUNDATION EVALUATES SIX SAMARITAN ALZHEIMER'S DRUGS.Samaritan Pharmaceuticals, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :SPHC), a biopharmaceutical company focused on bringing innovative life-saving drugs to suffering patients, has entered into an agreement with CHDI CHDI Cure Huntington's Disease Initiative Foundation, Inc. CHDI is a nonprofit organization Nonprofit Organization An association that is given tax-free status. Donations to a non-profit organization are often tax deductible as well. Notes: Examples of non-profit organizations are charities, hospitals and schools. pursuing the discovery and development of drugs to delay or slow the progression of Huntington's disease Huntington's disease, hereditary, acute disturbance of the central nervous system usually beginning in middle age and characterized by involuntary muscular movements and progressive intellectual deterioration; formerly called Huntington's chorea. (HD), an inherited disorder that causes programmed degeneration of brain cells. Per the agreement, Samaritan will grant CHDI an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan's Alzheimer's drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04, Sp-04m, and Sp-08, as possible therapeutics for HD. CHDI will pay for the cost of this evaluation and Samaritan will retain all rights in its compounds. Dr. Janet Greeson, Chief Executive Officer of Samaritan, commented: "We believe our CNS See Continuous net settlement. CNS See continuous net settlement (CNS). drugs hold a lot of promise to cognitively improve Alzheimer's patients and protect their brain from further damage; so we are extremely hopeful our drugs will demonstrate and hold the same promise for Huntington's disease." Robert Pacifici, CHDI's Chief Scientific Officer, stated, "We are intrigued with the potential that Samaritan's neuroprotective drugs have in combating Huntington's disease and look forward to evaluating the company's portfolio of Alzheimer's drugs. CHDI is dedicated to researching therapies that could help Huntington's disease patients and our team looks forward to the collaboration with Samaritan." About Huntington's Disease Huntington's disease is a familial disease, passed from parent to child through a mutation in a gene. Each child of an HD parent has a 50-50 chance of inheriting the HD gene, which causes programmed degeneration of brain cells and results in emotional disturbance Noun 1. emotional disturbance - any mental disorder not caused by detectable organic abnormalities of the brain and in which a major disturbance of emotions is predominant affective disorder, emotional disorder, major affective disorder , loss of intellectual faculties and uncontrolled movements. Most people with HD develop the symptoms at midlife mid·life n. See middle age. adj. Of, relating to, or characteristic of middle age. but in some people onset occurs in infancy or old age. The average survival time after onset is approximately fifteen to twenty years TWENTY YEARS. The lapse of twenty years raises a presumption of certain facts, and after such a time, the party against whom the presumption has been raised, will be required to prove a negative to establish his rights. 2. . It is estimated that about one in every 10,000 persons has the HD gene. At this time, there is no way to stop or reverse the course of HD. About CHDI Foundation, Inc. CHDI Foundation, Inc. is a non-profit organization pursuing a biotech approach to rapidly discover and develop drugs that prevent or slow Huntington's disease. Through collaborations with academic and industrial partners, CHDI participates in all aspects of drug discovery and development from discovery research through clinical development. About Samaritan Pharmaceuticals Samaritan Pharmaceuticals is an entrepreneurial biopharmaceutical company committed to bringing innovative life-saving drugs to suffering patients. For more information, visit http://www.samaritanpharma.com or call 212/825-3210. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion